Modalis Therapeutics Corporation
Climate Impact & Sustainability Data (2022)
Reporting Period: 2022
Environmental Metrics
ESG Focus Areas
- Environment
- Social
- Governance
Environmental Achievements
- Implemented wastewater treatment at US R&D facility
- Promoted energy consumption reduction and optimization through facility design, telework, and new HVAC/LED systems
- Implemented paperless initiatives and 100% recycling of items like toner cartridges
- Strict enforcement of proper separation and disposal of laboratory waste
Social Achievements
- Developed therapeutics targeting rare genetic disorders, aligning with the corporate philosophy of 'every life deserves attention'
- 51% female employees and 16% international employees at US R&D facility (as of Dec 31, 2022)
- Flexible work schedules and efforts to improve the working environment
- Securing and developing talent among scientists to drive innovation
- Making CRISPR-GNDM® technology available to partners to promote open innovation
Governance Achievements
- Five out of six Board of Directors are Outside Directors (one foreign, one female)
- Established auditing committee with three members having voting rights
- Separation of decision-making related to business matters and auditing functions
- Established Compliance Committee to ensure adherence to laws, business ethics, and company regulations
Climate Goals & Targets
Long-term Goals:
- Commoditization of genetic analysis
- Public acceptance of gene therapy
- Evolution of gene therapy technologies
Medium-term Goals:
- Clinical proof of concept for MDL-101 (2024-2025)
- Market approval and launch of GNDM-based product(s)
Short-term Goals:
- MDL-101 PreIND filing in 1Q 2023
- Initiation of clinical trial for MDL-101